AQS.V - Aequus Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.16
-0.01 (-5.88%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.17
Open0.17
Bid0.16 x 0
Ask0.17 x 0
Day's Range0.15 - 0.17
52 Week Range0.15 - 0.45
Volume340,827
Avg. Volume102,423
Market Cap12.87M
Beta-1.15
PE Ratio (TTM)N/A
EPS (TTM)-0.04
Earnings DateNov 27, 2018 - Dec 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • GlobeNewswire28 days ago

    Aequus Reports 5th Consecutive Quarter of Revenue Growth

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended June 30, 2018 (“Q2 2018”) and associated Company developments. Subsequent to the end of the quarter, the Company successfully closed two financings with total proceeds of $1,575,000.

  • GlobeNewswirelast month

    Aequus Closes Balance of $775,000 Equity Financing

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it has closed the balance of a non-brokered private placement announced August 9, 2018 for an aggregate 3,875,000 units of the Company (the “Units”) at a price of $0.20 per Unit (the “Offering Price”), for aggregate gross proceeds of $775,000 (the “Private Placement”). Each Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant”).

  • GlobeNewswire2 months ago

    Aequus Announces Fully-subscribed $775,000 Equity Financing

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it intends to complete a non-brokered private placement (the “Placement”) of 3,875,000 units of the Company (the “Units”) at a price of $0.20 per Unit (the “Offering Price”), for aggregate gross proceeds of $775,000 (the “Private Placement”). Each Unit shall consist of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant”).

  • GlobeNewswire2 months ago

    Aequus Announces Closing of $800,000 Equity Financing

    NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. VANCOUVER, British Columbia, July 31, 2018-- Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on ...

  • GlobeNewswire2 months ago

    Issuance of Stock Options

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), Aequus is pleased to announce it has granted incentive stock options to Damien King, a new director of the Company for the right to purchase up to an aggregate of 350,000 common shares of the Company. The terms of the stock options granted on July 23, 2016 are in accordance with the Company’s Stock Option Plan. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.

  • GlobeNewswire2 months ago

    Aequus Announces Proposed $800,000 Equity Financing To Next Edge Biotech Plus Fund

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it intends to complete a proposed equity financing of 4,000,000 units of the Company (the "Units") at a price of $0.20 per Unit (the "Offering Price"), for aggregate gross proceeds of $800,000 (the "Offering") to the Next Edge Bio-Tech Plus Fund under a prospectus supplement to the Company’s base shelf prospectus dated August 15, 2017, which prospectus supplement will be filed in the provinces of British Columbia, Alberta, Ontario, Saskatchewan and Manitoba. Each Unit shall consist of one common share of the Company and one-half of one non-transferrable common share purchase warrant (each, a "Warrant").

  • GlobeNewswire2 months ago

    Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal Patch

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”) is pleased to announce a recent expansion of the market opportunity for its reformulated anti-nausea transdermal patch, AQS1303, into the European market. Diclectin®, the oral reference product for AQS1303 for the treatment of nausea and vomiting of pregnancy, has recently received marketing authorization in the United Kingdom under the brand name Xonvea®. Aequus plans to launch AQS1303 in countries where an original oral form has been approved and an accelerated path to approval may exist for reformulated products.

  • GlobeNewswire2 months ago

    Aequus Extends and Enhances Commercial Agreement to Promote Vistitan in Canada

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), is pleased to announce that it has agreed to new terms for its promotional service agreement with Sandoz on PRVistitan™ (“Vistitan”) with improved economics and a term extension of an additional year. Aequus began promotional efforts in May 2016 for Vistitan (bimatoprost 0.03%, ophthalmic solution), which is approved in Canada for the reduction of elevated intraocular pressure (“IOP”) in patients with open angle glaucoma or ocular hypertension. Under the previous agreement, Aequus and Sandoz split revenues based upon an agreed to tiered structure over the term.

  • GlobeNewswire2 months ago

    Aequus Announces New Independent Director to its Board

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that following the completion of its Annual General Meeting held on July 10, 2018, Mr. Damien King has joined its Board of Directors to fill the seat previously held by Dr. Fotios Plakogiannis who did not stand for re-election. Mr. King is currently the Director of Sales with Merz Pharma Canada (“Merz”) and sits as a founding member of their Senior Leadership Team.

  • CNW Group7 months ago

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

  • PR Newswire7 months ago

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

    VANCOUVER, March 5, 2018 /CNW/ - Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (EHVVF) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave's bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.

  • PR Newswire7 months ago

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

    Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (EHVVF) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave's bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.

  • Marketwired8 months ago

    Aequus Announces Closing of $300,000 Equity Financing

    NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing,...